Spinal chemotherapy to help protect the brain during blinatumomab
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial studies giving medicine into the spinal fluid (intrathecal chemotherapy) to lower the risk of brain/nerve side effects from blinatumomab. It’s for adults with certain types of B-cell acute lymphoblastic leukemia (ALL) who are starting their first cycle.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are an adult starting your first cycle of blinatumomab for relapsed or hard-to-treat ALL, or MRD-positive disease
- You have adequate kidney and liver function based on recent lab tests
- You test negative for HIV
- If you can become pregnant, your pregnancy test is negative
- Your overall health movement/energy level is good (ECOG 0 to 2)
- You have no current signs of leukemia in the brain or spinal fluid
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if a shorter course of blinatumomab can remove minimal residual disease (MRD) — tiny traces of leukemia not seen under a microscope — in people with B-cell acute lymphoblastic leukemia after initial treatment.
This trial tests a treatment plan for adults with a type of blood cancer called ALL that is newly diagnosed and not Philadelphia chromosome-positive. The goal is to see how well the treatment works and if it is safe for patients who have not had prior therapy.
This study compares blinatumomab alone versus blinatumomab plus nivolumab in young people whose B-cell ALL has returned for the first time. It aims to see whether adding nivolumab improves control of the leukemia after relapse.
This trial tests a combination of a targeted drug (blinatumomab) with a lower dose of standard chemotherapy for adults newly diagnosed with a certain type of B-cell acute lymphoblastic leukemia. The goal is to see if this approach is effective and causes fewer side effects than full-dose chemotherapy.
This study compares two ways of giving blinatumomab (a drug that helps your immune system find and kill leukaemia cells): as a continuous intravenous (IV) infusion versus a simpler subcutaneous (under the skin) injection. It is for adults newly diagnosed with B-cell precursor ALL, and the goal is to see if the subcutaneous injection works just as well while being more convenient.
This trial tests whether a drug called blinatumomab can clear leftover leukemia cells in children with B-cell acute lymphoblastic leukemia (B-ALL) who still have traces of disease after standard treatment. It aims to reduce the chance of relapse.
Hear when a new Acute Lymphoblastic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.